Abbott Laboratories ($ABT) Stock Forecast: Down 10.2% Today

What is Abbott Laboratories?

Abbott Laboratories (ABT) is a health giant with a broad range of offerings in medical devices, diagnostics, nutrition, and pharmaceuticals, dedicated to enhancing healthcare through innovation.

Why is Abbott Laboratories going down?

ABT stock is down 10.2% on Jan 22, 2026 20:42

• ABT stock saw a significant decline of 7% post its latest financial results announcement.
• The market responded unfavorably to ABT's sales figure of $11.46 billion, which fell below the analyst forecast of $11.8 billion.
• The market is wary of the impact of the proposed $23 billion acquisition deal with Exact Sciences (EXAS) on ABT's stock performance.
• Though the company's earnings per share for the fourth quarter aligned with analyst predictions, the lower-than-expected sales figures have shaken investor confidence.

ABT Price Chart

ABT Technical Analysis

ABT News

Intel, GE Aerospace, Moderna, Abbott, Arista, Mobileye, McCormick, and More Movers

Stocks were on the rise Thursday following President Donald Trump's announcement of a "framework of a future deal" with NATO concerning Greenland. Equities maintained their gains after new data revealed that the Federal Reserve's preferred inflation gauge largely met expectations in November. The article lists Intel, GE Aerospace, Moderna, Abbott, Arista Networks, Mobileye, and McCormick as some of the day's movers.

https://www.barrons.com/articles/stock-movers-fd84ffe4?gaa_at=eafs&gaa_n=AWEtsqeIyyQrSYePnMO_kuiZJCwKVQ6ElqHna4gpF-y66fnLAlcRJJWDeM0X&gaa_ts=69726ed6&gaa_sig=yVxXH6HBRXaHssWj6sxLv-PWV-7szhhCGYeWnY8mDbYZ9dNyGg6CFHYbd__9U5562nscQrj1EPGTG6rRF8hMvg%3D%3D

Hologic Q1 Earnings Preview: How Should You Play the Stock Now?

Hologic (HOLX) is expected to announce its Q1 fiscal 2026 earnings on January 29, with analysts projecting a 5.8% increase in EPS and a 5% jump in revenues. The company holds a Zacks Rank #2 and a positive Earnings ESP, suggesting a high probability of exceeding estimates, building on a consistent track record of earnings beats. Strong performances are anticipated across its Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments, despite potential macroeconomic headwinds, while a pending acquisition by Blackstone and TPG positions the stock for a modest upside.

https://finviz.com/news/283855/hologic-q1-earnings-preview-how-should-you-play-the-stock-now

Johnson & Johnson stock holds steady as Guggenheim reiterates Buy rating

Guggenheim reiterated a Buy rating and a $227.00 price target for Johnson & Johnson (NYSE:JNJ) after the healthcare giant reported strong Q4 2025 financial results. The company's sales of $24.564 billion and EPS of $2.46 exceeded or met analyst expectations, driven by strong performance in its Innovative Medicine and MedTech segments. Despite potential for muted stock reaction due to recent gains, J&J issued a positive 2026 sales and EPS guidance.

https://www.investing.com/news/analyst-ratings/johnson--johnson-stock-holds-steady-as-guggenheim-reiterates-buy-rating-93CH-4460074

Erasca stock hits 52-week high at 10.46 USD

Erasca Inc. (ERAS) stock reached a new 52-week high of $10.46, reflecting a 405.03% increase over the past year, driven by investor confidence in its precision oncology treatments. The company recently announced a proposed $150 million public offering to raise capital and reported preliminary year-end cash and securities of approximately $341.8 million. Analysts at H.C. Wainwright and Stifel raised their price targets for Erasca based on promising clinical data for its ERAS-0015 molecular glue degrader and positive pipeline updates.

https://www.investing.com/news/company-news/erasca-stock-hits-52week-high-at-1046-usd-93CH-4460638

Abbott Dives 7% On Quarterly Upset As Exact Close Looms

Abbott Laboratories (ABT) stock dropped 7% after the health giant reported fourth-quarter adjusted income of $1.50 per share on $11.46 billion in sales, missing analyst sales expectations of $11.8 billion. This occurs as a $23 billion buyout deal with Exact Sciences (EXAS) is nearing completion. The company's fourth-quarter earnings per share matched analyst estimates, but the sales figure fell short, impacting investor confidence.

https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q4-2025/

Trending Today

Jupiter ($JUP) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

Abbott Laboratories Price History

16.09.2024 - ABT Stock was down 0.1%

• Despite strong Q3 earnings surpassing expectations, ABT's stock saw a bearish trend today.
• The market reaction may have been influenced by mixed U.S. stock futures trading, impacting investor sentiment towards healthcare stocks like ABT.
• Today’s 2.26% decline in stock price could be due to profit-taking by investors following a period of consistent growth.
• While ABT remains on track to meet its annual forecast, short-term market movements and overall market conditions likely played a role in today's bearish performance.

02.04.2025 - ABT Stock was up 2.8%

• ABT's stock price surged by 0.40% during the current market session, signaling strong bullish momentum.
• Despite a minor decline in the last month, the stock has notably jumped by 22.07% over the past year, reflecting promising long-term growth prospects.
• The optimistic momentum can be attributed to favorable market conditions, potential advancements in the healthcare industry, or a positive earnings outlook for the company.

05.00.2026 - ABT Stock was up 1.3%

• ABT witnessed a significant bullish movement today.
• This trend may be linked to the recent rise in institutional holdings by Asset Management One Co. Ltd., suggesting confidence in the company's performance and future prospects.
• Furthermore, Abbott Laboratories disclosed strong Q3 earnings, increased its quarterly dividend, and garnered a "Moderate Buy" consensus rating from analysts, likely contributing to market optimism and heightened investor interest in the stock.
• The positive institutional investment activity and favorable financial performance indicators have driven ABT's stock price higher today.

07.05.2024 - ABT Stock was up 1.3%

• ABT stock experienced a bullish movement today, likely driven by multiple factors:
• The positive outlook on dividend-paying companies in the current market environment could have attracted investors to ABT due to its strong dividend track record.
• The average brokerage recommendation of 1.50 for ABT, indicating a Strong Buy sentiment from analysts, might have boosted investor confidence in the stock.
• The technical issues leading to trading halts for NYSE stocks, including ABT, could have created volatility in the market, potentially leading to increased trading activity in ABT as investors sought stability in healthcare stocks.
• Overall, the combination of positive market sentiment towards dividend stocks, favorable analyst recommendations, and technical issues impacting trading on the NYSE likely contributed to ABT's bullish movement today.

17.06.2025 - ABT Stock was down 8.0%

• ABT stock faced a notable decline today, with a decrease of 8.07%.
• The company's third-quarter earnings projection, which fell below analyst expectations, is believed to have played a role in the significant drop in the stock price.
• Investors' reaction to the adjusted earnings outlook likely triggered a sell-off of ABT shares during the pre-market trading session.
• Heightened market sensitivity ahead of the upcoming second-quarter earnings release may have prompted investors to reposition themselves based on the revised forecasts.

16.03.2025 - ABT Stock was up 5.4%

• Abbott Laboratories reported positive Q1 earnings, with sales increasing by 7.2% and adjusted EPS surpassing consensus estimates, potentially influencing the uptick in ABT stock.
• The company's strong performance in the Medical Device segment, notably with products like FreeStyle Libre and heart-related devices, demonstrated its resilience in uncertain times and its ability to drive growth.
• The purchase of a substantial amount of ABT stock by a member of the House of Representatives might have boosted investor confidence in the company's future, leading to increased buying activity and pushing the stock price up.
• Despite the overall market decline witnessed today, Abbott Laboratories' robust financial results, favorable market sentiment, and strategic growth initiatives likely propelled the bullish trend in ABT stock.

15.09.2025 - ABT Stock was down 4.8%

• The stock of Abbott Laboratories (ABT) faced a downward trend in the market today.
• Negative market reaction followed the company's third-quarter sales, which were slightly below anticipated levels.
• Abbott Laboratories' revised fiscal 2025 guidance also played a role in driving down the stock price.
• Despite predictions of increased earnings per share for the third quarter, investor focus on sales performance and future prospects led to the bearish movement in the stock.

18.06.2024 - ABT Stock was down 1.2%

• Despite reporting strong Q2 earnings with EPS beating estimates, Abbott Laboratories (ABT) experienced a bearish movement in its stock.
• The market may have reacted negatively to a slight revenue miss, even though the full-year guidance was raised, indicating potential concerns about future performance.
• Investors might have been expecting higher revenue growth, leading to profit-taking and a bearish trend in the stock price.
• Market sentiment could have been influenced by broader economic conditions or global events, overshadowing the positive earnings beat.

22.00.2026 - ABT Stock was down 10.2%

• ABT stock saw a significant decline of 7% post its latest financial results announcement.
• The market responded unfavorably to ABT's sales figure of $11.46 billion, which fell below the analyst forecast of $11.8 billion.
• The market is wary of the impact of the proposed $23 billion acquisition deal with Exact Sciences (EXAS) on ABT's stock performance.
• Though the company's earnings per share for the fourth quarter aligned with analyst predictions, the lower-than-expected sales figures have shaken investor confidence.

22.00.2026 - ABT Stock was down 8.7%

• Abbott Laboratories (ABT) stock plummeted by 7% due to fourth-quarter sales falling short of analyst expectations, despite meeting EPS estimates.
• The pending $23 billion buyout deal with Exact Sciences (EXAS) added uncertainty and pressure on ABT's stock performance.
• The Medical Devices segment showed strong growth with a 12.3% increase in sales, but the overall revenue miss affected the stock negatively.
• The disappointing financial results and underwhelming sales figures are the main drivers behind the bearish movement of Abbott Laboratories' stock today.

22.00.2026 - ABT Stock was down 9.8%

• Abbott Laboratories (ABT) stock experienced a significant bearish movement, dropping 7% in response to its fourth-quarter financial results falling short of analyst expectations.
• The disappointment in sales figures, missing the $11.8 billion estimate, led to a loss in investor confidence and contributed to the stock slump.
• The looming $23 billion buyout deal with Exact Sciences added to the market uncertainty surrounding Abbott's future prospects, further impacting the bearish sentiment.
• Despite meeting EPS estimates and showcasing strong performance in its Medical Devices business with a 12.3% sales increase, the overall revenue miss overshadowed these positive aspects and drove the stock price down.

17.06.2025 - ABT Stock was down 6.3%

• A weak earnings projection for the third quarter by Abbott Laboratories, falling below market expectations, caused a significant drop in the stock's value.
• Analysts, who had adjusted their predictions prior to the earnings announcement, were anticipating an uptick in quarterly earnings per share. The unexpected weaker guidance likely surprised investors, contributing to the bearish trend.
• The general pessimism towards ABT was magnified by the overall downtrend in U.S. stock futures, with the Dow futures declining by around 0.2% on the same day.